1. Regulation of M2-type pyruvate kinase mediated by the high-affinity IgE receptors is required for mast cell degranulation.
- Author
-
Ryu, H., Walker, J. K. L., Kim, S., Koo, N., Barak, L. S., Noguchi, T., Kang, B. Y., and Kim, K.-M.
- Subjects
MAST cells ,PYRUVATE kinase ,ALLERGIES ,GLYCOLYSIS ,LABORATORY rats ,BIOCHEMICAL genetics - Abstract
Background and purpose:M
2 -type pyruvate kinase (M2 PK) was found to interact directly with the ‘ITAM’ region of the γ chain of the high-affinity IgE receptor (FcɛRI). Our hypothesis was that mast cell degranulation might require the FcɛRI-mediated inhibition of M2 PK activity.Experimental approach:In rat basophilic leukaemia (RBL-2H3) cells, the effects of directly inhibiting M2 PK or preventing the FcɛRI-mediated inhibition of M2 PK (disinhibition) on degranulation was measured by hexosaminidase release. Effects of blocking the FcɛRI-mediated inhibition of M2 PK was also assessed in vivo in a mouse model of allergen-induced airway hyper-responsiveness.Key results:Activation of FcɛRI in RBL-2H3 cells caused the rapid phosphorylation of tyrosine residues in M2 PK, associated with a decrease in M2 PK enzymatic activity. There was an inverse correlation between M2 PK activity and mast cell degranulation. FcɛRI-mediated inhibition of M2 PK involved Src kinase, phosphatidylinositol 3-kinase, PKC and calcium. Direct inhibition of M2 PK potentiated FcɛRI-mediated degranulation and prevention of the FcɛRI-mediated inhibition of M2 PK attenuated mast cell degranulation. Transfection of RBL-2H3 cells with M1 PK which prevents FcɛRI-induced inhibition of M2 PK, markedly reduced their degranulation and exogenous M1 PK (i.p.) inhibited ovalbumin-induced airway hyper-responsiveness in vivo.Conclusions and implications:We have identified a new control point and a novel biochemical pathway in the process of mast cell degranulation. Our study suggests that the FcɛRI-mediated inhibition of M2 PK is a crucial step in responses to allergens. Moreover, the manipulation of glycolytic processes and intermediates could provide novel strategies for the treatment of allergic diseases.British Journal of Pharmacology (2008) 154, 1035–1046; doi:10.1038/bjp.2008.148; published online 21 April 2008 [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF